BIIB Biogen
Nasdaq · SEC CIK 875045 · EDGAR
- Bought, last 12 months
- $585.12 1 purchases by 1 insiders
- Sold, last 12 months
- $905.4K 3 sales by 2 insiders
- Filings on record
- 238 since 2021-07-02, latest 2026-09-03 16:14
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Singhal Priya | Head of Development | — | $665.7K |
| Minor Lloyd | Dir | — | $239.7K |
| Murphy Nicole | Head of Pharm Ops, Tech | $585.12 | — |
| Godbout Sean | CAO | — | — |
| Pangalos Menelas N | Dir | — | — |
| Grogan Jane | Head of Research | — | — |
| LANGER SUSAN | Dir | — | — |
| Keeney Adam | Head of Corp. Development | — | — |
| Izzar Rachid | Head of Gbl Product Strat | — | — |
| Patolawala Monish D | Dir | — | — |
Transactions 322
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MT | 2026-08-05 16:03 | 2026-08-03+ | BIIB | Minor Lloyd | Dir | S - Sale | $202.15 | -1,186 | 2,689 | -31% | -$239.7K |
| 2026-06-11 17:50 | 2026-06-09 | BIIB | HAWKINS WILLIAM A | Dir | A - Grant | $0.00 | +1,505 | 10.4K | +17% | $0 | |
| 2026-06-11 17:47 | 2026-06-09 | BIIB | SHERWIN STEPHEN A | Dir | A - Grant | $0.00 | +1,505 | 15.2K | +11% | $0 | |
| 2026-06-11 17:46 | 2026-06-09 | BIIB | Rowinsky Eric K | Dir | A - Grant | $0.00 | +1,505 | 25.8K | +6% | $0 | |
| 2026-06-11 17:44 | 2026-06-09 | BIIB | Mantas Jesus B | Dir | A - Grant | $0.00 | +1,505 | 11.3K | +15% | $0 | |
| 2026-06-11 17:34 | 2026-06-09 | BIIB | LANGER SUSAN | Dir | A - Grant | $0.00 | +1,505 | 6,634 | +29% | $0 | |
| 2026-06-11 17:32 | 2026-06-09 | BIIB | Patolawala Monish D | Dir | A - Grant | $0.00 | +1,505 | 5,215 | +41% | $0 | |
| D | 2026-06-11 17:21 | 2026-06-09 | BIIB | Pangalos Menelas N | Dir | M - OptEx | $0.00 | +2,370 | 2,370 | New | $0 |
| D | 2026-06-11 17:21 | 2026-06-09 | BIIB | Pangalos Menelas N | Dir | A - Grant | $0.00 | +1,505 | 3,875 | +64% | $0 |
| 2026-06-11 17:17 | 2026-06-09 | BIIB | Minor Lloyd | Dir | A - Grant | $0.00 | +1,505 | 3,875 | +64% | $0 | |
| 2026-06-11 17:09 | 2026-06-09 | BIIB | Freire Maria C | Dir | A - Grant | $0.00 | +2,005 | 8,820 | +29% | $0 | |
| D | 2026-05-05 16:11 | 2026-05-01 | BIIB | Keeney Adam | Head of Corp. Development | M - OptEx | $0.00 | +939 | 6,820 | +16% | $0 |
| D | 2026-05-05 16:11 | 2026-05-01 | BIIB | Keeney Adam | Head of Corp. Development | F - Tax | $187.06 | -455 | 6,365 | -7% | -$85.1K |
| D | 2026-04-03 16:05 | 2026-04-01 | BIIB | Godbout Sean | CAO | M - OptEx | $0.00 | +181 | 1,396 | +15% | $0 |
| D | 2026-04-03 16:05 | 2026-04-01 | BIIB | Godbout Sean | CAO | F - Tax | $183.78 | -54 | 1,342 | -4% | -$9,924 |
| D | 2026-02-17 | 2026-02-12 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | P - Purchase | $195.04 | +3 | 19.6K | +0.0% | +$585.12 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Godbout Sean | CAO | M - OptEx | $0.00 | +1,079 | 980.67 | New | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Godbout Sean | CAO | F - Tax | $201.18 | -359 | 1,215 | -23% | -$72.2K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | +6,889 | 11.8K | +141% | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Izzar Rachid | Head of Gbl Product Strat | F - Tax | $201.18 | -2,038 | 11.0K | -16% | -$410.0K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Gregory Ginger | EVP, Human Resources | M - OptEx | $0.00 | +7,183 | 20.4K | +54% | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Gregory Ginger | EVP, Human Resources | F - Tax | $201.18 | -2,589 | 22.4K | -10% | -$520.9K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | +6,900 | 12.1K | +132% | $0 |
| D | 2026-02-10 | 2026-02-09 | BIIB | Singhal Priya | Head of Development | S - Sale+OE | $199.83 | -2,660 | 8,043 | -25% | -$531.5K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Singhal Priya | Head of Development | F - Tax | $201.18 | -2,468 | 7,432 | -25% | -$496.5K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Kramer Robin | CFO | M - OptEx | $0.00 | +5,003 | 8,801 | +132% | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Kramer Robin | CFO | F - Tax | $201.18 | -1,543 | 9,024 | -15% | -$310.4K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Keeney Adam | Head of Corp. Development | F - Tax | $201.18 | -1,583 | 3,597 | -31% | -$318.5K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Keeney Adam | Head of Corp. Development | M - OptEx | $0.00 | +5,080 | 4,186 | New | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | ALEXANDER SUSAN H | EVP CLO | M - OptEx | $0.00 | +9,046 | 38.5K | +31% | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | ALEXANDER SUSAN H | EVP CLO | F - Tax | $201.18 | -3,504 | 37.4K | -9% | -$704.9K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Grogan Jane | Head of Research | F - Tax | $201.18 | -991 | 2,769 | -26% | -$199.4K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | +3,258 | 3,176 | New | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $201.18 | -3,339 | 15.3K | -18% | -$671.7K |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +8,725 | 21.0K | +71% | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | M - OptEx | $0.00 | +24.5K | 36.5K | +202% | $0 |
| DM | 2026-02-10 | 2026-02-06 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | F - Tax | $201.18 | -11.0K | 21.1K | -34% | -$2.21M |
| D | 2026-02-03 | 2026-01-30 | BIIB | Singhal Priya | Head of Development | F - Tax | $179.89 | -582 | 7,019 | -8% | -$104.7K |
| D | 2026-02-03 | 2026-02-02 | BIIB | Singhal Priya | Head of Development | S - Sale+OE | $179.30 | -748 | 6,271 | -11% | -$134.1K |
| D | 2026-02-03 | 2026-01-30 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | +1,829 | 7,601 | +32% | $0 |
| D | 2025-12-03 | 2025-12-01 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | M - OptEx | $0.00 | +7,040 | 19.8K | +55% | $0 |
| D | 2025-12-03 | 2025-12-01 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | F - Tax | $177.78 | -3,404 | 16.4K | -17% | -$605.2K |
| D | 2025-11-04 | 2025-10-31 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | +695 | 2,128 | +48% | $0 |
| D | 2025-11-04 | 2025-10-31 | BIIB | Grogan Jane | Head of Research | F - Tax | $154.27 | -337 | 1,791 | -16% | -$52.0K |
| D | 2025-10-06 | 2025-10-02 | BIIB | Godbout Sean | CAO | M - OptEx | $0.00 | +26 | 502.67 | +5% | $0 |
| D | 2025-10-06 | 2025-10-02 | BIIB | Godbout Sean | CAO | F - Tax | $155.25 | -8 | 494.67 | -2% | -$1,242 |
| D | 2025-09-02 | 2025-08-29 | BIIB | Singhal Priya | Head of Development | F - Tax | $132.22 | -807 | 6,289 | -11% | -$106.7K |
| D | 2025-09-02 | 2025-08-29 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | +1,669 | 7,096 | +31% | $0 |
| D | 2025-09-02 | 2025-09-02 | BIIB | Singhal Priya | Head of Development | S - Sale+OE | $133.55 | -517 | 5,772 | -8% | -$69.0K |
| 2025-07-16 | 2025-07-08 | BIIB | Izzar Rachid | Head of Gbl Product Strat | S - Sale | $135.00 | -2,223 | 6,330 | -26% | -$300.1K | |
| 2025-06-18 | 2025-06-17 | BIIB | SHERWIN STEPHEN A | Dir | A - Grant | $0.00 | +2,370 | 13.7K | +21% | $0 | |
| 2025-06-18 | 2025-06-17 | BIIB | DORSA CAROLINE | Dir | A - Grant | $0.00 | +3,160 | 31.0K | +11% | $0 | |
| 2025-06-18 | 2025-06-17 | BIIB | Mantas Jesus B | Dir | A - Grant | $0.00 | +2,370 | 9,758 | +32% | $0 | |
| 2025-06-18 | 2025-06-17 | BIIB | Minor Lloyd | Dir | A - Grant | $0.00 | +2,370 | 2,370 | New | $0 | |
| 2025-06-18 | 2025-06-17 | BIIB | HAWKINS WILLIAM A | Dir | A - Grant | $0.00 | +2,370 | 8,860 | +37% | $0 | |
| 2025-06-18 | 2025-06-17 | BIIB | Rowinsky Eric K | Dir | A - Grant | $0.00 | +2,370 | 24.3K | +11% | $0 | |
| 2025-06-18 | 2025-06-17 | BIIB | Freire Maria C | Dir | A - Grant | $0.00 | +2,370 | 6,815 | +53% | $0 | |
| 2025-06-18 | 2025-06-17 | BIIB | Patolawala Monish D | Dir | A - Grant | $0.00 | +2,370 | 3,710 | +177% | $0 | |
| 2025-06-18 | 2025-06-17 | BIIB | LANGER SUSAN | Dir | A - Grant | $0.00 | +2,370 | 5,129 | +86% | $0 | |
| 2025-05-20 | 2025-05-19 | BIIB | Singhal Priya | Head of Development | S - Sale | $126.25 | -3,806 | 5,427 | -41% | -$480.5K | |
| 2025-05-05 | 2025-05-02 | BIIB | DORSA CAROLINE | Dir | P - Purchase | $122.72 | +1,235 | 27.8K | +5% | +$151.6K | |
| D | 2025-05-05 | 2025-05-01 | BIIB | Keeney Adam | Head of Corp. Development | F - Tax | $120.93 | -454 | 2,384 | -16% | -$54.9K |
| D | 2025-05-05 | 2025-05-01 | BIIB | Keeney Adam | Head of Corp. Development | M - OptEx | $0.00 | +938 | 2,838 | +49% | $0 |
| 2025-03-10 | 2025-03-07 | BIIB | SHERWIN STEPHEN A | Dir | S - Sale | $150.02 | -8,760 | 11.3K | -44% | -$1.31M | |
| D | 2025-02-12 | 2025-02-10 | BIIB | ALEXANDER SUSAN H | EVP CLO | M - OptEx | $0.00 | +2,575 | 37.1K | +7% | $0 |
| D | 2025-02-12 | 2025-02-10 | BIIB | ALEXANDER SUSAN H | EVP CLO | F - Tax | $142.54 | -807 | 36.3K | -2% | -$115.0K |
| D | 2025-02-12 | 2025-02-10 | BIIB | Gregory Ginger | EVP, Human Resources | M - OptEx | $0.00 | +2,159 | 18.2K | +13% | $0 |
| D | 2025-02-12 | 2025-02-10 | BIIB | Gregory Ginger | EVP, Human Resources | F - Tax | $142.54 | -634 | 17.6K | -3% | -$90.4K |
| D | 2025-02-12 | 2025-02-10 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +2,272 | 14.7K | +18% | $0 |
| D | 2025-02-12 | 2025-02-10 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $142.54 | -670 | 14.1K | -5% | -$95.5K |
| D | 2025-02-12 | 2025-02-10 | BIIB | MCDONNELL MICHAEL R | EVP, CFO | M - OptEx | $0.00 | +3,257 | 25.7K | +15% | $0 |
| D | 2025-02-12 | 2025-02-10 | BIIB | MCDONNELL MICHAEL R | EVP, CFO | F - Tax | $142.54 | -1,371 | 24.3K | -5% | -$195.4K |
| D | 2025-02-12 | 2025-02-10 | BIIB | Kramer Robin | CAO | M - OptEx | $0.00 | +834 | 8,257 | +11% | $0 |
| D | 2025-02-12 | 2025-02-10 | BIIB | Kramer Robin | CAO | F - Tax | $142.54 | -245 | 8,012 | -3% | -$34.9K |
| D | 2025-02-12 | 2025-02-10 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | +1,515 | 8,998 | +20% | $0 |
| D | 2025-02-12 | 2025-02-10 | BIIB | Izzar Rachid | Head of Gbl Product Strat | F - Tax | $142.54 | -445 | 8,553 | -5% | -$63.4K |
| D | 2025-02-12 | 2025-02-10 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | +1,212 | 9,423 | +15% | $0 |
| D | 2025-02-12 | 2025-02-10 | BIIB | Singhal Priya | Head of Development | F - Tax | $142.54 | -357 | 9,066 | -4% | -$50.9K |
| DM | 2025-02-11 | 2025-02-07 | BIIB | Izzar Rachid | Head of Gbl Product Strat | F - Tax | $141.35 | -1,165 | 6,059 | -16% | -$164.7K |
| DM | 2025-02-11 | 2025-02-07 | BIIB | Izzar Rachid | Head of Gbl Product Strat | M - OptEx | $0.00 | +3,844 | 7,224 | +114% | $0 |
| DM | 2025-02-10 | 2025-02-07 | BIIB | MCDONNELL MICHAEL R | EVP, CFO | M - OptEx | $0.00 | +4,551 | 23.2K | +24% | $0 |
| DM | 2025-02-10 | 2025-02-07 | BIIB | MCDONNELL MICHAEL R | EVP, CFO | F - Tax | $141.35 | -1,502 | 21.0K | -7% | -$212.3K |
| DM | 2025-02-10 | 2025-02-07 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | M - OptEx | $0.00 | +4,042 | 13.1K | +45% | $0 |
| DM | 2025-02-10 | 2025-02-07 | BIIB | Murphy Nicole | Head of Pharm Ops, Tech | F - Tax | $141.35 | -1,223 | 11.1K | -10% | -$172.9K |
| DM | 2025-02-10 | 2025-02-07 | BIIB | Gregory Ginger | EVP, Human Resources | F - Tax | $141.35 | -1,040 | 16.1K | -6% | -$147.0K |
| DM | 2025-02-10 | 2025-02-07 | BIIB | Gregory Ginger | EVP, Human Resources | M - OptEx | $0.00 | +3,436 | 16.6K | +26% | $0 |
| D | 2025-02-10 | 2025-02-07 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | F - Tax | $141.35 | -3,201 | 12.8K | -20% | -$452.5K |
| D | 2025-02-10 | 2025-02-07 | BIIB | Viehbacher Christopher | Pres, CEO, Dir | M - OptEx | $0.00 | +9,008 | 16.0K | +129% | $0 |
| DM | 2025-02-10 | 2025-02-07 | BIIB | ALEXANDER SUSAN H | EVP CLO | M - OptEx | $0.00 | +4,130 | 35.1K | +13% | $0 |
| DM | 2025-02-10 | 2025-02-07 | BIIB | ALEXANDER SUSAN H | EVP CLO | F - Tax | $141.35 | -1,234 | 33.1K | -4% | -$174.4K |
| DM | 2025-02-10 | 2025-02-07 | BIIB | Kramer Robin | CAO | F - Tax | $141.35 | -476 | 7,423 | -6% | -$67.3K |
| DM | 2025-02-10 | 2025-02-07 | BIIB | Kramer Robin | CAO | M - OptEx | $0.00 | +1,491 | 7,667 | +24% | $0 |
| D | 2025-02-10 | 2025-02-07 | BIIB | Keeney Adam | Head of Corp. Development | F - Tax | $141.35 | -563 | 1,900 | -23% | -$79.6K |
| D | 2025-02-10 | 2025-02-07 | BIIB | Keeney Adam | Head of Corp. Development | M - OptEx | $0.00 | +1,801 | 2,463 | +272% | $0 |
| D | 2025-02-10 | 2025-02-07 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | +2,216 | 8,892 | +33% | $0 |
| D | 2025-02-10 | 2025-02-07 | BIIB | Singhal Priya | Head of Development | F - Tax | $141.35 | -681 | 8,211 | -8% | -$96.3K |
| D | 2025-02-10 | 2025-02-07 | BIIB | Grogan Jane | Head of Research | F - Tax | $141.35 | -443 | 1,433 | -24% | -$62.6K |
| D | 2025-02-10 | 2025-02-07 | BIIB | Grogan Jane | Head of Research | M - OptEx | $0.00 | +1,385 | 1,876 | +282% | $0 |
| D | 2025-02-03 | 2025-01-31 | BIIB | Singhal Priya | Head of Development | F - Tax | $143.93 | -578 | 6,676 | -8% | -$83.2K |
| D | 2025-02-03 | 2025-01-31 | BIIB | Singhal Priya | Head of Development | M - OptEx | $0.00 | +1,828 | 7,254 | +34% | $0 |
Purchase Sale Sale after option exercise All abbreviations